Azione NSB NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue NeuroScientific Biopharmaceuticals Limited

Azioni

NSB

AU0000012973

Tempo differito Australian S.E.
Altri mercati azionari
 04:22:27 07/05/2024 		Variaz. 5gg Var. 1 gen.
0,046 AUD -4,17% Grafico intraday di NeuroScientific Biopharmaceuticals Limited -4,17% +4,55%
20/03 NeuroScientific Biopharmaceuticals ottiene un rimborso fiscale per R&S di 2 milioni di dollari australiani per l'anno fiscale 2023; le azioni salgono del 6%. MT
27/02 NeuroScientific Biopharmaceuticals Limited riporta i risultati degli utili per il semestre conclusosi il 31 dicembre 2023 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors
NeuroScientific Biopharmaceuticals CEO to Step Down
NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023
Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023
Neuroscientific Biopharmaceuticals Limited Announces Board Changes
NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director
Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022
Neuroscientific Biopharmaceuticals Files New Patent for Multiple Sclerosis Treatment; Shares Jump 7%
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"
NeuroScientific Biopharmaceuticals Names Interim CEO; Shares Climb 12%
NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO
NeuroScientific Biopharmaceuticals Limited Announces Management Changes
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as CEO
Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione NSB
  4. Notizie NeuroScientific Biopharmaceuticals Limited
  5. Altre lingue